Care of the Liver Transplant Patient

Disease-a-Month

Volumn 54, Issue 7, 2008, Pages 486-507

  Kallwitz, Eric R ^a   Cotler, Scott J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMIODARONE; CARBAMAZEPINE; CHICKENPOX VACCINE; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; DILTIAZEM; ETHINYLESTRADIOL; HEPATITIS VACCINE; INFLUENZA VACCINE; MACROLIDE; MENINGITIS VACCINE; METHYLPREDNISOLONE; METOCLOPRAMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NAFCILLIN; OMEPRAZOLE; PHENOBARBITAL; PHENYTOIN; PNEUMOCOCCUS VACCINE; PREDNISONE; PROTEINASE INHIBITOR; RAPAMYCIN; RIFAMPICIN; TACROLIMUS; TETANUS TOXOID; TRIAZOLE; UNINDEXED DRUG; VERAPAMIL;

ADRENAL INSUFFICIENCY; ALCOHOL LIVER DISEASE; AUTOIMMUNE HEPATITIS; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; BASAL CELL CARCINOMA; BILE DUCT DISEASE; BILE DUCT OBSTRUCTION; BILE LEAKAGE; BONE MARROW SUPPRESSION; CANCER RISK; CARDIOVASCULAR DISEASE; CATARACT; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DUCTOPENIC REJECTION; DYSLIPIDEMIA; EDEMA; ESOPHAGUS CANCER; GALACTOSEMIA; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; GLYCOGEN STORAGE DISEASE; GRAFT RECIPIENT; GRAFT REJECTION; HEADACHE; HEMOCHROMATOSIS; HEPATITIS B; HEPATITIS C; HIRSUTISM; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOMAGNESEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFLUENZA VACCINATION; KAPOSI SARCOMA; KIDNEY DISEASE; KIDNEY FAILURE; LIVER TRANSPLANTATION; LOW DRUG DOSE; LYMPHOPROLIFERATIVE DISEASE; MELANOMA; MENINGITIS; METABOLIC BONE DISEASE; METABOLIC DISORDER; MOOD DISORDER; NEPHROTIC SYNDROME; NONALCOHOLIC FATTY LIVER; OBESITY; OROPHARYNX CANCER; OSTEOLYSIS; OSTEOPOROSIS; PATIENT CARE; PERIPHERAL NEUROPATHY; POSTOPERATIVE COMPLICATION; POSTRANSPLANT DIABETES; PREGNANCY; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PSYCHOSIS; REVIEW; SEIZURE; SEROMA; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; TETANUS PROPHYLAXIS; TREMOR; VIRUS INFECTION; WEIGHT GAIN; WILSON DISEASE; WOUND INFECTION;

GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION;

EID: 44949259099     PISSN: 00115029     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.disamonth.2008.03.003     Document Type: Review

References (170)

1. McCashland T.M. Posttransplantation care: role of the primary care physician versus transplant center. Liver Transplant 7 (2001) S2-S12
2. Roberts M.S., Angus D.C., Bryce C.L., et al. Survival after liver transplantation in the United States: a disease-specific analysis of the UNOS database. Liver Transplant 10 (2004) 886-897
3. Schrem H., Luck R., Becker T., et al. Update on liver transplantation using cyclosporine. Transplant Proc 36 (2004) 2525-2531
4. Post D.J., Douglas D.D., and Mulligan D.C. Immunosuppression in liver transplantation. Liver Transplant 11 (2005) 1307-1314
5. Komolmit P., and Davies M.H. Tacrolimus in liver transplantation. Exp Opin Invest Drugs 8 (1999) 1239-1254
6. Fulton B., and Markham A. Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Drugs 51 (1996) 278-298
7. Fung J., Kelly D., Kadry Z., et al. Immunosuppression in liver transplantation: beyond calcineurin inhibitors. Liver Transplant 11 (2005) 267-280
8. Kauffman H.M., Cherikh W.S., Cheng Y., et al. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 80 (2005) 883-889
9. Toso C., Meeberg G.A., Bigam D.L., et al. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation 83 (2007) 1162-1168
10. Soin A.S., Rasmussen A., Jamieson N.V., et al. CsA levels in the early posttransplant period-predictive of chronic rejection in liver transplantation?. Transplantation 27 (1995) 1119-1123
11. Wiesner R.H., Demetris A.J., Belle S.H., et al. Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology 28 (1998) 638-645
12. Ramji A., Yoshida E.M., Bain V.G., et al. Late acute rejection after liver transplantation: the Western Canada experience. Liver Transplant 8 (2002) 945-951
13. Wiesner R.H. Advances in diagnosis, prevention, and management of hepatic allograft rejection. Clin Chem 40 (1994) 2174-2185
14. Wiesner R.H., Ludwig J., van Hoek B., et al. Current concepts in cell-mediated hepatic allograft rejection leading to ductopenia and liver failure. Hepatology 14 (1991) 721-729
15. Klintmalm G.B., Nery J.R., Husberg B.S., et al. Rejection in liver transplantation. Hepatology 10 (1989) 978-985
16. Neuberger J., and Adams D.H. What is the significance of acute liver allograft rejection?. J Hepatol 29 (1998) 143-150
17. Dousset B., Conti F., Cherruau B., et al. Is acute rejection deleterious to long-term liver allograft function?. J Hepatol 29 (1998) 660-668
18. Adams D.H., and Neuberger J.M. Patterns of graft rejection following liver transplantation. J Hepatol 10 (1990) 113-119
19. Mor E., Gonwa T.A., Husberg B.S., et al. Late-onset acute rejection in orthotopic liver transplantation: associated risk factors and outcome. Transplantation 54 (1992) 821-824
20. Ludwig J. Terminology of hepatic allograft rejection (glossary). Semin Liver Dis 12 (1992) 89-92
21. Ludwig J., Wiesner R.H., Batts K.P., et al. The acute vanishing bile duct syndrome (acute irreversible rejection) after orthotopic liver transplantation. Hepatology 7 (1987) 476-483
22. Pirsch J.D., Kalayoglu M., Hafez G.R., et al. Evidence that the vanishing bile duct syndrome is vanishing. Transplantation 49 (1990) 1015-1018
23. Batts K.P. Acute and chronic hepatic allograft rejection: pathology and classification. Liver Transplant Surg 5 (1999) S21-S29
24. Park J.S., Kim M.H., Lee S.K., et al. Efficacy of endoscopic and percutaneous treatments for biliary complications after cadaveric and living donor liver transplantation. Gastrointest Endosc 57 (2003) 78-85
25. Qian Y.B., Liu C.L., Lo C.M., et al. Risk factors for biliary complications after liver transplantation. Arch Surg 139 (2004) 1101-1105
26. Rerknimitr R., Sherman S., Fogel E.L., et al. Biliary tract complications after orthotopic liver transplantation with choledochocholedochostomy anastomosis: endoscopic findings and results of therapy. Gastrointest Endosc 55 (2002) 224-231
27. Sawyer R.G., and Punch J.D. Incidence and management of biliary complications after 291 liver transplants following the introduction of transcystic stenting. Transplantation 66 (1998) 1201-1207
28. Thethy S., Thomson B., Pleass H., et al. Management of biliary tract complications after orthotopic liver transplantation. Clin Transplant 18 (2004) 647-653
29. Greif F., Bronsther O.L., Van Thiel D.H., et al. The incidence, timing, and management of biliary tract complications after orthotopic liver transplantation. Ann Surg 219 (1994) 40-45
30. Moser M.A., and Wall W.J. Management of biliary problems after liver transplantation. Liver Transplant 7 (2001) S46-S52
31. Scatton O., Meunier B., Cherqui D., et al. Randomized trial of choledochocholedochostomy with or without a T tube in orthotopic liver transplantation. Ann Surg 233 (2001) 432-437
32. Vougas V., Rela M., Gane E., et al. A prospective randomised trial of bile duct reconstruction at liver transplantation: T tube or no T tube?. Transplant Int 9 (1996) 392-395
33. Tung B.Y., and Kimmey M.B. Biliary complications of orthotopic liver transplantation. Dig Dis 17 (1999) 133-144
34. Hampe T., Dogan A., Encke J., et al. Biliary complications after liver transplantation. Clin Transplant 20 suppl 17 (2006) 93-96
35. Verdonk R.C., Buis C.I., Porte R.J., et al. Biliary complications after liver transplantation: a review. Scand J Gastroenterol 243 (2006) 89-101
36. Jagannath S., and Kalloo A.N. Biliary complications after liver transplantation. Curr Treat Options Gastroenterol 5 (2002) 101-112
37. Morelli J., Mulcahy H.E., Willner I.R., et al. Long-term outcomes for patients with post-liver transplant anastomotic biliary strictures treated by endoscopic stent placementj. Gastrointest Endosc 58 (2003) 374-379
38. Mahajani R.V., Cotler S.J., and Uzer M.F. Efficacy of endoscopic management of anastomotic biliary strictures after hepatic transplantation. Endoscopy 32 (2000) 943-949
39. Moench C., Moench K., Lohse A.W., et al. Prevention of ischemic-type biliary lesions by arterial back-table pressure perfusion. Liver Transplant 9 (2003) 285-289
40. Parry S.D., and Muiesan P. Cholangiopathy and the biliary cast syndrome. Eur J Gastroenterol Hepatol 15 (2003) 341-343
41. Barton P., Steininger R., Maier A., et al. Biliary sludge after liver transplantation. II. Treatment with interventional techniques versus surgery and/or oral chemolysis. AJR Am J Roentgenol 164 (1995) 865-869
42. Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transplant 4 suppl 10 (2004) 160-163
43. Iinuma Y., Senda K., Fujihara N., et al. Surgical site infection in living-donor liver transplant recipients: a prospective study. Transplantation 78 (2004) 704-709
44. Petri J.B., Schurk S., Gebauer S., et al. Cyclosporine A delays wound healing and apoptosis and suppresses activin beta-A expression in rats. Eur J Dermatol 8 (1998) 104-113
45. Stephan R.N., Munschauer C.E., and Kumar M.S. Surgical wound infection in renal transplantation: outcome data in 102 consecutive patients without perioperative systemic antibiotic coverage. Arch Surg 132 (1997) 1315-1318
46. Singh N. Infectious diseases in the liver transplant recipient. Semin Gastrointest Dis 9 (1998) 136-146
47. Fishman J.A., and Rubin R.H. Infection in organ-transplant recipients. N Engl J Med 338 (1998) 1741-1751
48. Shibolet O., Ilan Y., Kalish Y., et al. Late cytomegalovirus disease following liver transplantation. Transplant Int 16 (2003) 861-865
49. Singh N., Muder R.R., Yu V.L., et al. Legionella infection in liver transplant recipients: implications for management. Transplantation 56 (1993) 1549-1551
50. Singh N., Gayowski T., Wagener M., et al. Pulmonary infections in liver transplant recipients receiving tacrolimus. Changing pattern of microbial etiologies. Transplantation 61 (1996) 396-401
51. Mizuno S., Zendejas I.R., Reed A.I., et al. Listeria monocytogenes following orthotopic liver transplantation: central nervous system involvement and review of the literature. World J Gastroenterol 13 (2007) 4391-4393
52. Wu G., Vilchez R.A., Eidelman B., et al. Cryptococcal meningitis: an analysis among 5,521 consecutive organ transplant recipients. Transplant Infect Dis 4 (2002) 183-188
53. Laryea M., Watt K.D., Molinari M., et al. Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. Liver Transplant 13 (2007) 1109-1114
54. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
55. Sawyer R.G., Pelletier S.J., and Pruett T.L. Increased early morbidity and mortality with acceptable long-term function in severely obese patients undergoing liver transplantation. Clin Transplant 13 (1999) 126-130
56. Munoz S.J., Deems R.O., Moritz M.J., et al. Hyperlipidemia and obesity after orthotopic liver transplantation. Transplant Proc 23 (1991) 1480-1483
57. Stegall M.D., Everson G., Schroter G., et al. Metabolic complications after liver transplantation. Diabetes, hypercholesterolemia, hypertension, and obesity. Transplantation 60 (1995) 1057-1060
58. Canzanello V.J., Schwartz L., Taler S.J., et al. Evolution of cardiovascular risk after liver transplantation: a comparison of cyclosporine A and tacrolimus (FK506). Liver Transplant Surg 3 (1997) 1-9
59. Richards J., Gunson B., Johnson J., et al. Weight gain and obesity after liver transplantation. Transplant Int 18 (2005) 461-466
60. Navasa M., Bustamante J., Marroni C., et al. Diabetes mellitus after liver transplantation: prevalence and predictive factors. J Hepatol 25 (1996) 64-71
61. John P.R., and Thuluvath P.J. Outcome of patients with new-onset diabetes mellitus after liver transplantation compared with those without diabetes mellitus. Liver Transplant 8 (2002) 708-713
62. Steinmuller T.H., Stockmann M., Bechstein W.O., et al. Liver transplantation and diabetes mellitus. Exp Clin Endocrinol Diabetes 108 (2000) 401-405
63. Baid S., Cosimi A.B., Farrell M.L., et al. Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation 72 (2001) 1066-1072
64. AlDosary A.A., Ramji A.S., Elliott T.G., et al. Post-liver transplantation diabetes mellitus: an association with hepatitis C. Liver Transplant 8 (2002) 356-361
65. Tueche S.G. Diabetes mellitus after liver transplant new etiologic clues and cornerstones for understanding. Transplant Proc 35 (2003) 1466-1468
66. Cotler S.J., Kallwitz E., TenCate V., et al. Diabetes and hepatic oxidative damage are associated with hepatitis C progression after liver transplantation. Transplantation 84 (2007) 587-591
67. Foxton M.R., Quaglia A., Muiesan P., et al. The impact of diabetes mellitus on fibrosis progression in patients transplanted for hepatitis C. Am J Transplant 6 (2006) 1922-1929
68. Canzanello V.J., Textor S.C., Taler S.J., et al. Late hypertension after liver transplantation: a comparison of cyclosporine and tacrolimus (FK 506). Liver Transplant Surg 4 (1998) 328-334
69. Sheiner P.A., Magliocca J.F., Bodian C.A., et al. Long-term medical complications in patients surviving ≥5 years after liver transplant. Transplantation 69 (2000) 781-789
70. Rabkin J.M., Corless C.L., Rosen H.R., et al. Immunosuppression impact on long-term cardiovascular complications after liver transplantation. Am J Surg 183 (2002) 595-599
71. Neal D.A., Brown M.J., Wilkinson I.B., et al. Mechanisms of hypertension after liver transplantation. Transplantation 79 (2005) 935-940
72. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. The US Multicenter FK506 Liver Study Group. N Engl J Med 331 (1994) 1110-1115
73. Lerman A., Click R.L., Narr B.J., et al. Elevation of plasma endothelin associated with systemic hypertension in humans following orthotopic liver transplantation. Transplantation 51 (1991) 646-650
74. Guckelberger O., Bechstein W.O., Neuhaus R., et al. Cardiovascular risk factors in long-term follow-up after orthotopic liver transplantation. Clin Transplant 11 (1997) 60-65
75. Gisbert C., Prieto M., Berenguer M., et al. Hyperlipidemia in liver transplant recipients: prevalence and risk factors. Liver Transplant Surg 3 (1997) 416-422
76. Charco R., Cantarell C., Vargas V., et al. Serum cholesterol changes in long-term survivors of liver transplantation: a comparison between cyclosporine and tacrolimus therapy. Liver Transplant Surg 5 (1999) 204-208
77. Manzarbeitia C., Reich D.J., Rothstein K.D., et al. Tacrolimus conversion improves hyperlipidemic states in stable liver transplant recipients. Liver Transplant 7 (2001) 93-99
78. Trotter J.F., Wachs M.E., Trouillot T.E., et al. Dyslipidemia during sirolimus therapy in liver transplant recipients occurs with concomitant cyclosporine but not tacrolimus. Liver Transplant 7 (2001) 401-408
79. Zachoval R., Gerbes A.L., Schwandt P., et al. Short-term effects of statin therapy in patients with hyperlipoproteinemia after liver transplantation: results of a randomized cross-over trial. J Hepatol 35 (2001) 86-91
80. Broeders N., Knoop C., Antoine M., et al. Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?. Nephrol Dial Transplant 15 (2000) 1993-1999
81. Abbasoglu O., Levy M.F., Brkic B.B., et al. Ten years of liver transplantation: an evolving understanding of late graft loss. Transplantation 64 (1997) 1801-1807
82. Giannini S., Nobile M., Dalle Carbonare L., et al. Vertebral morphometry by X-ray absorptiometry before and after liver transplant: a cross-sectional study. Eur J Gastroenterol Hepatol 13 (2001) 1201-1207
83. Figueiredo F.A., Brandao C., Perez Rde M., et al. Low bone mineral density in noncholestatic liver cirrhosis: prevalence, severity and prediction. Arq Gastroenterol 40 (2003) 152-158
84. Guichelaar M.M., Malinchoc M., Sibonga J., et al. Bone metabolism in advanced cholestatic liver disease: analysis by bone histomorphometry. Hepatology 36 (2002) 895-903
85. Hodgson S.F., Dickson E.R., Wahner H.W., et al. Bone loss and reduced osteoblast function in primary biliary cirrhosis. Ann Intern Med 103 (1985) 855-860
86. Monegal A., Navasa M., Guanabens N., et al. Osteoporosis and bone mineral metabolism disorders in cirrhotic patients referred for orthotopic liver transplantation. Calcif Tissue Int 60 (1997) 148-154
87. McCaughan G.W., and Feller R.B. Osteoporosis in chronic liver disease: pathogenesis, risk factors, and management. Dig Dis 12 (1994) 223-231
88. Eastell R., Dickson E.R., Hodgson S.F., et al. Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis. Hepatology 14 (1991) 296-300
89. McDonald J.A., Dunstan C.R., Dilworth P., et al. Bone loss after liver transplantation. Hepatology 14 (1991) 613-619
90. Gonwa T.A., Morris C.A., Goldstein R.M., et al. Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome: experience in 300 patients. Transplantation 51 (1991) 428-430
91. Gonwa T.A. Hypertension and renal dysfunction in long-term liver transplant recipients. Liver Transplant 7 (2001) S22-S26
92. Andoh T.F., Burdmann E.A., and Bennett W.M. Nephrotoxicity of immunosuppressive drugs: experimental and clinical observations. Semin Nephrol 17 (1997) 34-45
93. Kopp J.B., and Klotman P.E. Cellular and molecular mechanisms of cyclosporin nephrotoxicity. J Am Soc Nephrol 1 (1990) 162-179
94. Nankivell B.J., Borrows R.J., Fung C.L., et al. The natural history of chronic allograft nephropathy. N Engl J Med 349 (2003) 2326-2333
95. Pawarode A., Fine D.M., and Thuluvath P.J. Independent risk factors and natural history of renal dysfunction in liver transplant recipients. Liver Transplant 9 (2003) 741-747
96. Reich D., Rothstein K., Manzarbeitia C., et al. Common medical diseases after liver transplantation. Semin Gastrointest Dis 9 (1998) 110-125
97. Gonwa T.A., Mai M.L., Melton L.B., et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation 72 (2001) 1934-1939
98. Fisher N.C., Nightingale P.G., Gunson B.K., et al. Chronic renal failure following liver transplantation: a retrospective analysis. Transplantation 66 (1998) 59-66
99. Kim D.Y., Lim C., Parasuraman R., et al. Renal disease burden following liver transplantation. Transplant Proc 38 (2006) 3663-3665
100. Jain A.B., Yee L.D., Nalesnik M.A., et al. Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data. Transplantation 66 (1998) 1193-1200
101. Sheil A.G. Malignancy following liver transplantation: a report from the Australian Combined Liver Transplant Registry. Transplant Proc 27 (1995) 1247
102. Kelly D.M., Emre S., Guy S.R., et al. Liver transplant recipients are not at increased risk for nonlymphoid solid organ tumors. Cancer 83 (1998) 1237-1243
103. Levy M., Backman L., Husberg B., et al. De novo malignancy following liver transplantation: a single-center study. Transplant Proc 25 (1993) 1397-1399
104. Jain A., DiMartini A., Kashyap R., et al. Long-term follow-up after liver transplantation for alcoholic liver disease under tacrolimus. Transplantation 70 (2000) 1335-1342
105. Berenguer M., Prieto M., Bustamante M., et al. [Incidence of de novo neoplasms after liver transplantation]. Med Clin 111 (1998) 481-484
106. Xiol X., Guardiola J., Menendez S., et al. Risk factors for development of de novo neoplasia after liver transplantation. Liver Transplant 7 (2001) 971-975
107. Yao F.Y., Gautam M., Palese C., et al. De novo malignancies following liver transplantation: a case-control study with long-term follow-up. Clin Transplant 20 (2006) 617-623
108. Nalesnik M.A. Lymphoproliferative disease in organ transplant recipients. Springer Semin Immunopathol 13 (1991) 199-216
109. Nalesnik M.A., Jaffe R., Starzl T.E., et al. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol 133 (1988) 173-192
110. Cherikh W.S., Kauffman H.M., McBride M.A., et al. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation 76 (2003) 1289-1293
111. Bustami R.T., Ojo A.O., Wolfe R.A., et al. Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant 4 (2004) 87-93
112. Kremers W.K., Devarbhavi H.C., Wiesner R.H., et al. Post-transplant lymphoproliferative disorders following liver transplantation: incidence, risk factors and survival. Am J Transplant 6 (2006) 1017-1024
113. Vallejo G.H., Romero C.J., and de Vicente J.C. Incidence and risk factors for cancer after liver transplantation. Crit Rev Oncol Hematol 56 (2005) 87-99
114. Ben-Ari Z., Amlot P., Lachmanan S.R., et al. Posttransplantation lymphoproliferative disorder in liver recipients: characteristics, management, and outcome. Liver Transplant Surg 5 (1999) 184-191
115. Starzl T.E., Nalesnik M.A., Porter K.A., et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1 (1984) 583-587
116. McCarthy M., Ramage J., McNair A., et al. The clinical diversity and role of chemotherapy in lymphoproliferative disorder in liver transplant recipients. J Hepatol 27 (1997) 1015-1021
117. Norin S., Kimby E., Ericzon B.G., et al. Posttransplant lymphoma: a single-center experience of 500 liver transplantations. Med Oncol 21 (2004) 273-284
118. Bouwes Bavinck J.N., Hardie D.R., Green A., et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia. A follow-up study. Transplantation 61 (1996) 715-721
119. Perera G.K., Child F.J., Heaton N., et al. Skin lesions in adult liver transplant recipients: a study of 100 consecutive patients. Br J Dermatol 154 (2006) 868-872
120. Jimenez-Romero C., Manrique Municio A., Marques Medina E., et al. Incidence of de novo nonmelanoma skin tumors after liver transplantation for alcoholic and nonalcoholic liver diseases. Transplant Proc 38 (2006) 2505-2507
121. Herrero J.I., Espana A., Quiroga J., et al. Nonmelanoma skin cancer after liver transplantation. Study of risk factors. Liver Transplant 11 (2005) 1100-1106
122. Euvrard S., Kanitakis J., Pouteil-Noble C., et al. Aggressive squamous cell carcinomas in organ transplant recipients. Transplant Proc 27 (1995) 1767-1768
123. Euvrard S., Kanitakis J., and Claudy A. Skin cancers after organ transplantation. N Engl J Med 348 (2003) 1681-1691
124. Mithoefer A.B., Supran S., and Freeman R.B. Risk factors associated with the development of skin cancer after liver transplantation. Liver Transplant 8 (2002) 939-944
125. Duvoux C., Delacroix I., Richardet J.P., et al. Increased incidence of oropharyngeal squamous cell carcinomas after liver transplantation for alcoholic cirrhosis. Transplantation 67 (1999) 418-421
126. Jimenez C., Manrique A., Marques E., et al. Incidence and risk factors for the development of lung tumors after liver transplantation. Transplant Int 20 (2007) 57-63
127. Jimenez C., Marques E., Manrique A., et al. Incidence and risk factors of development of lung tumors after liver transplantation. Transplant Proc 37 (2005) 3970-3972
128. Bleday R., Lee E., Jessurun J., et al. Increased risk of early colorectal neoplasms after hepatic transplant in patients with inflammatory bowel disease. Dis Colon Rectum 36 (1993) 908-912
129. Silva M.A., Jambulingam P.S., and Mirza D.F. Colorectal cancer after orthotopic liver transplantation. Crit Rev Oncol Hematol 56 (2005) 147-153
130. Chazouilleres O., Kim M., Combs C., et al. Quantitation of hepatitis C virus RNA in liver transplant recipients. Gastroenterology 106 (1994) 994-999
131. Ferrell L.D., Wright T.L., Roberts J., et al. Hepatitis C viral infection in liver transplant recipients. Hepatology 16 (1992) 865-876
132. Feray C., Caccamo L., Alexander G.J., et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. Gastroenterology 117 (1999) 619-625
133. Ghobrial R.M., Farmer D.G., Baquerizo A., et al. Orthotopic liver transplantation for hepatitis C: outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience. Ann Surg 229 (1999) 824-831
134. Prieto M., Berenguer M., Rayon J.M., et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 29 (1999) 250-256
135. Testa G., Crippin J.S., Netto G.J., et al. Liver transplantation for hepatitis C: recurrence and disease progression in 300 patients. Liver Transplant 6 (2000) 553-561
136. Velidedeoglu E., Mange K.C., Frank A., et al. Factors differentially correlated with the outcome of liver transplantation in hcv+ and HCV- recipients. Transplantation 77 (2004) 1834-1842
137. Dixon L.R., and Crawford J.M. Early histologic changes in fibrosing cholestatic hepatitis C. Liver Transplant 13 (2007) 219-226
138. Neumann U.P., Berg T., Bahra M., et al. Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up. Transplantation 77 (2004) 226-231
139. Forman L.M., Lewis J.D., Berlin J.A., et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 122 (2002) 889-896
140. Rodriguez-Luna H., Khatib A., Sharma P., et al. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series. Transplantation 77 (2004) 190-194
141. Chalasani N., Manzarbeitia C., Ferenci P., et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology 41 (2005) 289-298
142. Eisenbach C., Sauer P., Mehrabi A., et al. Prevention of hepatitis B virus recurrence after liver transplantation. Clin Transplant 20 suppl 17 (2006) 111-116
143. Markowitz J.S., Martin P., Conrad A.J., et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 28 (1998) 585-589
144. Gautam M., Cheruvattath R., and Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transplant 12 (2006) 1813-1824
145. Khalaf H., Mourad W., El-Sheikh Y., et al. Liver transplantation for autoimmune hepatitis: a single-center experience. Transplant Proc 39 (2007) 1166-1170
146. Lohse A.W., Weiler-Norman C., and Burdelski M. De novo autoimmune hepatitis after liver transplantation. Hepatol Res 37 suppl 3 (2007) S462
147. Liermann Garcia R.F., Evangelista Garcia C., McMaster P., et al. Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center. Hepatology 33 (2001) 22-27
148. Guy J.E., Qian P., Lowell J.A., et al. Recurrent primary biliary cirrhosis: peritransplant factors and ursodeoxycholic acid treatment post-liver transplant. Liver Transplant 11 (2005) 1252-1257
149. Sylvestre P.B., Batts K.P., Burgart L.J., et al. Recurrence of primary biliary cirrhosis after liver transplantation: histologic estimate of incidence and natural history. Liver Transplant 9 (2003) 1086-1093
150. Khettry U., Anand N., Faul P.N., et al. Liver transplantation for primary biliary cirrhosis: a long-term pathologic study. Liver Transplant 9 (2003) 87-96
151. Schmitz V., Neumann U.P., Puhl G., et al. Surgical complications and long-term outcome of different biliary reconstructions in liver transplantation for primary sclerosing cholangitis-choledochoduodenostomy versus choledochojejunostomy. Am J Transplant 6 (2006) 379-385
152. Brandsaeter B., Schrumpf E., Bentdal O., et al. Recurrent primary sclerosing cholangitis after liver transplantation: a magnetic resonance cholangiography study with analyses of predictive factors. Liver Transplant 11 (2005) 1361-1369
153. Everson G., Bharadhwaj G., House R., et al. Long-term follow-up of patients with alcoholic liver disease who underwent hepatic transplantation. Liver Transplant Surg 3 (1997) 263-274
154. DiMartini A., Day N., Dew M.A., et al. Alcohol consumption patterns and predictors of use following liver transplantation for alcoholic liver disease. Liver Transplant 12 (2006) 813-820
155. Tome S., and Lucey M.R. Timing of liver transplantation in alcoholic cirrhosis. J Hepatol 39 (2003) 302-307
156. Kowdley K.V., Hassanein T., Kaur S., et al. Primary liver cancer and survival in patients undergoing liver transplantation for hemochromatosis. Liver Transplant Surg 1 (1995) 237-241
157. Tung B.Y., Farrell F.J., McCashland T.M., et al. Long-term follow-up after liver transplantation in patients with hepatic iron overload. Liver Transplant Surg 5 (1999) 369-374
158. Farrell F.J., Nguyen M., Woodley S., et al. Outcome of liver transplantation in patients with hemochromatosis. Hepatology 20 (1994) 404-410
159. Kowdley K.V., Brandhagen D.J., Gish R.G., et al. Survival after liver transplantation in patients with hepatic iron overload: the national hemochromatosis transplant registry. Gastroenterology 129 (2005) 494-503
160. Powell L.W. Hemochromatosis: the impact of early diagnosis and therapy. Gastroenterology 110 (1996) 1304-1307
161. Kotlyar D.S., Campbell M.S., and Reddy K.R. Recurrence of diseases following orthotopic liver transplantation. Am J Gastroenterol 101 (2006) 1370-1378
162. Charlton M., Kasparova P., Weston S., et al. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transplant 7 (2001) 608-614
163. Groth C.G., Dubois R.S., Corman J., et al. Metabolic effects of hepatic replacement in Wilson's disease. Transplant Proc 5 (1973) 829-833
164. Filipponi F., Soubrane O., Labrousse F., et al. Liver transplantation for end-stage liver disease associated with alpha-1-antitrypsin deficiency in children: pretransplant natural history, timing and results of transplantation. J Hepatol 20 (1994) 72-78
165. Cundy T.F., O'Grady J.G., and Williams R. Recovery of menstruation and pregnancy after liver transplantation. Gut 31 (1990) 337-338
166. Framarino Dei Malatesta M., Rossi M., Rocca B., et al. Fertility following solid organ transplantation. Transplant Proc 39 (2007) 2001-2004
167. Armenti V.T., Radomski J.S., Moritz M.J., et al. Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. Clin Transplant (2005) 69-83
168. Christopher V., Al-Chalabi T., Richardson P.D., et al. Pregnancy outcome after liver transplantation: a single-center experience of 71 pregnancies in 45 recipients. Liver Transplant 12 (2006) 1138-1143
169. Jabiry-Zieniewicz Z., Bobrowska K., Kaminski P., et al. Low-dose hormonal contraception after liver transplantation. Transplant Proc 39 (2007) 1530-1532
170. Sibanda N., Briggs J.D., Davison J.M., et al. Pregnancy after organ transplantation: a report from the UK Transplant pregnancy registry. Transplantation 83 (2007) 1301-1307